Recent market strength lifted the Nifty 50 above the 25,000 mark and the Sensex beyond 81,100, driven largely by financial powerhouses like SBI, HDFC Bank, and ICICI Bank. However, profit-taking emerged across IT and metal counters, leaving stocks like Infosys and Tata Steel among the key laggards. Amid this sector rotation, technical calls have been issued for Mankind Pharma, CDSL, and Aegis Logistics based on double bottom reversals and support-zone recoveries. All three picks carry two-month investment horizons alongside defined stop-loss thresholds to manage downside risk.
Key points
Mankind Pharma is recommended for purchase above ₹2,675 with a two-month target price of…: Mankind Pharma is recommended for purchase above ₹2,675 with a two-month target price of ₹2,950.
Aegis Logistics offers an entry point above ₹1,230 supported by buyer interest near the ₹…: Aegis Logistics offers an entry point above ₹1,230 supported by buyer interest near the ₹1,100 zone.
IT and metal stocks faced notable profit-booking despite the broader market's extended up…: IT and metal stocks faced notable profit-booking despite the broader market's extended upward momentum.
Sources checked by our analysis pipeline: 1
Stock market recap: As the week began, markets emerged from a phase of measured consolidation with volatility building beneath the surface. The gradual swings of the previous series gave way to stronger directional conviction, driving a sharp rally from the opening session.
On Monday, Sensex climbed 107.25 point to settle at 81,106.65, while the Nifty rose 58.25 points, or 0.23 per cent, to close at 25,044.65.
Markets were shut on Tuesday for Diwali-Balipratipada.
Three stocks to trade, recommended by NeoTrader’s Raja Venkatraman
MANKIND (current market price ₹2,668.30)
- Why it’s recommended: Mankind Pharma Ltd is one of India's leading pharmaceutical and healthcare companies, ranking among the top 4 pharmaceutical firms in India by domestic sales and #1 by prescription volume. Since May 2026 the lack of upward momentum had pushed the prices lower only to test key important levels has been spent in declining phase. In the recent past we can note that the prices have attempted to form a double bottom and is showing some volume lead recovery. The strong Relative Strength Divergence from lower levels is indicating a…
Financial analysts at Bank of America have detailed the critical forces shaping the future trajectory of Indian equities. Their assessment evaluates the specific positive catalysts that could propel the benchmark index upward while measuring key vulnerabilities that threaten momentum. This dual perspective provides market participants with essential parameters for gauging the sustainability of the domestic equity market's prospective growth.
Regulators are penalizing deceptive marketing tactics that leave deposit customers with lower yields than expected during monetary policy tightening cycles. Australian authorities initiated legal proceedings in the NSW Supreme Court after determining promotional materials misled customers about compounding returns. The financial institution chose not to contest the matter, acknowledging it breached its legal duties to deliver services fairly.
Domestic equities are positioned for early gains following a strong advance in early derivative contracts, extending momentum from the previous session's modest advance. Despite mixed international signals and ongoing overbought conditions, persistent dip-buying continues to provide a solid foundation for Indian benchmarks. Investors are now closely monitoring broader Asian trends and energy price movements for further directional cues.